These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26660394)

  • 1. LNK mutations and myeloproliferative disorders.
    McMullin MF; Cario H
    Am J Hematol; 2016 Feb; 91(2):248-51. PubMed ID: 26660394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
    Maslah N; Cassinat B; Verger E; Kiladjian JJ; Velazquez L
    Leukemia; 2017 Aug; 31(8):1661-1670. PubMed ID: 28484264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
    Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
    Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
    Baran-Marszak F; Magdoud H; Desterke C; Alvarado A; Roger C; Harel S; Mazoyer E; Cassinat B; Chevret S; Tonetti C; Giraudier S; Fenaux P; Cymbalista F; Varin-Blank N; Le Bousse-Kerdilès MC; Kiladjian JJ; Velazquez L
    Blood; 2010 Dec; 116(26):5961-71. PubMed ID: 20870899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nonsynonymous LNK polymorphism associated with idiopathic erythrocytosis.
    McMullin MF; Wu C; Percy MJ; Tong W
    Am J Hematol; 2011 Nov; 86(11):962-4. PubMed ID: 21990094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].
    Chen Y; Wu XQ; Han CS; Zhu P; Wei JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1309-12. PubMed ID: 24156456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.
    Jiang J; Balcerek J; Rozenova K; Cheng Y; Bersenev A; Wu C; Song Y; Tong W
    J Clin Invest; 2012 Jun; 122(6):2079-91. PubMed ID: 22546852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant CALR and LNK mutations leading to essential thrombocythemia with erythrocytosis.
    Luque Paz D; Boyer F; Beucher A; Bouvier A; Jouanneau-Courville R; Guardiola P; Lambert D; Delneste Y; Hunault M; Blanchet O; Ugo V
    Blood Cells Mol Dis; 2018 Jul; 71():75-76. PubMed ID: 29703677
    [No Abstract]   [Full Text] [Related]  

  • 10. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
    Gery S; Cao Q; Gueller S; Xing H; Tefferi A; Koeffler HP
    J Leukoc Biol; 2009 Jun; 85(6):957-65. PubMed ID: 19293402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.
    Gery S; Gueller S; Chumakova K; Kawamata N; Liu L; Koeffler HP
    Blood; 2007 Nov; 110(9):3360-4. PubMed ID: 17693582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible new LNK mutations in myeloproliferative neoplasms.
    Ha JS; Jeon DS
    Am J Hematol; 2011 Oct; 86(10):866-8. PubMed ID: 21922527
    [No Abstract]   [Full Text] [Related]  

  • 13. LNK mutations in JAK2 mutation-negative erythrocytosis.
    Lasho TL; Pardanani A; Tefferi A
    N Engl J Med; 2010 Sep; 363(12):1189-90. PubMed ID: 20843259
    [No Abstract]   [Full Text] [Related]  

  • 14. The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling.
    Devallière J; Charreau B
    Biochem Pharmacol; 2011 Nov; 82(10):1391-402. PubMed ID: 21723852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.
    Spolverini A; Pieri L; Guglielmelli P; Pancrazzi A; Fanelli T; Paoli C; Bosi A; Nichele I; Ruggeri M; Vannucchi AM
    Haematologica; 2013 Sep; 98(9):e101-2. PubMed ID: 23812944
    [No Abstract]   [Full Text] [Related]  

  • 16. LNK can also be mutated outside PH and SH2 domains in myeloproliferative neoplasms with and without V617FJAK2 mutation.
    Hurtado C; Erquiaga I; Aranaz P; Miguéliz I; García-Delgado M; Novo FJ; Vizmanos JL
    Leuk Res; 2011 Nov; 35(11):1537-9. PubMed ID: 21794913
    [No Abstract]   [Full Text] [Related]  

  • 17. Lnk constrains myeloproliferative diseases in mice.
    Bersenev A; Wu C; Balcerek J; Jing J; Kundu M; Blobel GA; Chikwava KR; Tong W
    J Clin Invest; 2010 Jun; 120(6):2058-69. PubMed ID: 20458146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
    Oh ST; Simonds EF; Jones C; Hale MB; Goltsev Y; Gibbs KD; Merker JD; Zehnder JL; Nolan GP; Gotlib J
    Blood; 2010 Aug; 116(6):988-92. PubMed ID: 20404132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the adaptor protein LNK in normal and malignant hematopoiesis.
    Gery S; Koeffler HP
    Oncogene; 2013 Jun; 32(26):3111-8. PubMed ID: 23045270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
    Koren-Michowitz M; Gery S; Tabayashi T; Lin D; Alvarez R; Nagler A; Koeffler HP
    Br J Haematol; 2013 Jun; 161(6):811-20. PubMed ID: 23590807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.